{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:40:25Z","timestamp":1788954025774,"version":"build-2803163510"},"reference-count":32,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAD"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) and Alzheimer\u2019s disease (AD) are the most common\nforms of neurodegenerative disorders. The aim of the current work is to study the potential of\nsome new indanone derivatives for the treatment of these neurological disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A new series of 4-(2-oxo-2-aminoethoxy)-2-benzylidene substituted indanone derivatives\nhave been synthesized and studied for anti-Parkinsonian and anti-Alzheimer\u2019s effects. Substitution\nof different aminoalkyl functionalities at the para position of 2-benzylidene moiety of\nindanone ring resulted in the formation of potent anti-parkinsonian and anti-Alzheimer\u2019s agents\n(5-10). The neuroprotective effects of newly synthesized compounds were evaluated using\nperphenazine (PPZ)-induced catatonia in rats and LPS-induced cognitive deficits in mice models.\nFurther, in silico molecular modelling studies of the new indanone derivatives were performed by\ndocking against the 3D structures of various neuroinflammatory mediators, such as interleukin-1\u03b2\n(IL-1\u03b2), tumor necrosis factor-\u03b1 (TNF-\u03b1) and monoamine oxidase-B (MAO-B), to gain the mechanistic\ninsights of their anti-Alzheimer\u2019s and antiparkinsonian effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The newly synthesized indanone analogues 5-10 were found effective against PPZinduced\nmotor dysfunction and LPS-induced memory impairment in animal models. Among\nall the synthesized analogues, morpholine-substituted indanone 9 displayed maximum\nanti-parkinsonian activity, even better than the standard drug L-DOPA, while pyrrolidine and\npiperidine substituted analogues 5 and 6 were found to be the most potent anti-Alzheimer\u2019s\nagents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The new 2-arylidene-1-indanone analogues show good potential as promising leads\nfor designing compounds against Parkinson\u2019s and Alzheimer\u2019s diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1573409919666221129155110","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T07:17:25Z","timestamp":1669965445000},"page":"94-107","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Synthesis, in silico Studies and Pharmacological Evaluation of a New\nSeries of Indanone Derivatives as Anti-Parkinsonian and Anti-Alzheimer\u2019s\nAgents"],"prefix":"10.2174","volume":"19","author":[{"given":"Ranju","family":"Bansal","sequence":"first","affiliation":[{"name":"University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Singh","sequence":"additional","affiliation":[{"name":"University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratibha","family":"Rana","sequence":"additional","affiliation":[{"name":"University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"145","volume":"2","author":"Ramanan V.K.","year":"2013","unstructured":"Ramanan V.K.; Saykin A.J.; Pathways to neurodegeneration: Mechanistic insights from GWAS in Alzheimer\u2019s disease, Parkinson\u2019s disease, and related disorders. Am J Neurodegener Dis 2013,2(3),145-175","journal-title":"Am J Neurodegener Dis"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1172\/JCI200317522","volume":"111","author":"Przedborski S.","year":"2003","unstructured":"Przedborski S.; Vila M.; Jackson-Lewis V.; Series introduction: Neurodegeneration: What is it and where are we? J Clin Invest 2003,111(1),3-10","journal-title":"J Clin Invest"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.pneurobio.2005.06.004","volume":"76","author":"Block M.L.","year":"2005","unstructured":"Block M.L.; Hong J.S.; Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Prog Neurobiol 2005,76(2),77-98","journal-title":"Prog Neurobiol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fneur.2011.00068","volume":"2","author":"Seidl S.E.","year":"2011","unstructured":"Seidl S.E.; Potashkin J.A.; The promise of neuroprotective agents in Parkinson\u2019s disease. Front Neurol 2011,2,68-69","journal-title":"Front Neurol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/med.10026","volume":"23","author":"Bachurin S.O.","year":"2003","unstructured":"Bachurin S.O.; Medicinal chemistry approaches for the treatment and prevention of Alzheimer\u2019s disease. Med Res Rev 2003,23(1),48-88","journal-title":"Med Res Rev"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.3390\/molecules25081909","volume":"25","author":"Kerru N.","year":"2020","unstructured":"Kerru N.; Gummidi L.; Maddila S.; Gangu K.K.; Jonnalagadda S.B.; A review on recent advances in nitrogen-containing molecules and their biological applications. Molecules 2020,25(8),1909","journal-title":"Molecules"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3762\/bjoc.13.48","volume":"13","author":"Turek M.","year":"2017","unstructured":"Turek M.; Szcz\u0119sna D.; Koprowski M.; Ba\u0142czewski P.; Synthesis of 1-indanones with a broad range of biological activity. Beilstein J Org Chem 2017,13,451-494","journal-title":"Beilstein J Org Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1016\/j.bmcl.2008.06.039","volume":"18","author":"Saxena H.O.","year":"2008","unstructured":"Saxena H.O.; Faridi U.; Srivastava S.; Kumar J.K.; Darokar M.P.; Luqman S.; Chanotiya C.S.; Krishna V.; Negi A.S.; Khanuja S.P.S.; Gallic acid-based indanone derivatives as anticancer agents. Bioorg Med Chem Lett 2008,18(14),3914-3918","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=9","first-page":"935","volume":"7","author":"Josh C.","year":"2017","unstructured":"Josh C.; Menezes J.M.D.; Arylidene indanone scaffold: Medicinal chemistry and structure activity relationship. J Med Chem 2017,7,935","journal-title":"J Med Chem"},{"key":"ref=10","first-page":"801","volume":"24","author":"Sharma G.S.","year":"2010","unstructured":"Sharma G.S.; Saxena A.K.; Synthesis and biological evaluation of chalcones having heterosubstituents. Indian J Pharm Sci 2010,24,801-806","journal-title":"Indian J Pharm Sci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/jnci\/92.3.217","volume":"92","author":"Leoni L.M.","year":"2000","unstructured":"Leoni L.M.; Hamel E.; Genini D.; Shih H.; Carrera C.J.; Cottam H.B.; Carson D.A.; Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells. J Natl Cancer Inst 2000,92(3),217-224","journal-title":"J Natl Cancer Inst"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejmech.2017.06.032","volume":"138","author":"Patil S.A.","year":"2017","unstructured":"Patil S.A.; Patil R.; Patil S.A.; Recent developments in biological activities of indanones. Eur J Med Chem 2017,138,182-198","journal-title":"Eur J Med Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/cmdc.201500059","volume":"10","author":"Mostert S.","year":"2015","unstructured":"Mostert S.; Petzer A.; Petzer J.P.; Indanones as high-potency reversible inhibitors of monoamine oxidase. ChemMedChem 2015,10(5),862-873","journal-title":"ChemMedChem"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"8483","DOI":"10.1021\/jm300978h","volume":"55","author":"Huang L.","year":"2012","unstructured":"Huang L.; Lu C.; Sun Y.; Mao F.; Luo Z.; Su T.; Jiang H.; Shan W.; Li X.; Multitarget-directed benzylideneindanone derivatives: Anti-\u03b2-amyloid (A\u03b2) aggregation, antioxidant, metal chelation, and monoamine oxidase B (MAO-B) inhibition properties against Alzheimer\u2019s disease. J Med Chem 2012,55(19),8483-8492","journal-title":"J Med Chem"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ejmech.2014.09.081","volume":"87","author":"Huang L.","year":"2014","unstructured":"Huang L.; Miao H.; Sun Y.; Meng F.; Li X.; Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer\u2019s disease. Eur J Med Chem 2014,87,429-439","journal-title":"Eur J Med Chem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.3390\/ijms20092293","volume":"20","author":"Batista C.R.A.","year":"2019","unstructured":"Batista C.R.A.; Gomes G.F.; Candelario-Jalil E.; Fiebich B.L.; de Oliveira A.C.P.; Lipopolysaccharide-induced neuroinflammation as a bridge to understand neurodegeneration. Int J Mol Sci 2019,20(9),2293","journal-title":"Int J Mol Sci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/17425255.2017.1273901","volume":"13","author":"Riederer P.","year":"2017","unstructured":"Riederer P.; M\u00fcller T.; Use of monoamine oxidase inhibitors in chronic neurodegeneration. Expert Opin Drug Metab Toxicol 2017,13(2),233-240","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1080\/17460441.2019.1637415","volume":"14","author":"Guglielmi P.","year":"2019","unstructured":"Guglielmi P.; Carradori S.; Ammazzalorso A.; Secci D.; Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: Is there room for improvement? Expert Opin Drug Discov 2019,14(10),995-1035","journal-title":"Expert Opin Drug Discov"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1016\/j.bmcl.2016.08.067","volume":"26","author":"Nel M.S.","year":"2016","unstructured":"Nel M.S.; Petzer A.; Petzer J.P.; Legoabe L.J.; 2-Benzylidene-1-indanone derivatives as inhibitors of monoamine oxidase. Bioorg Med Chem Lett 2016,26(19),4599-4605","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.bioorg.2016.09.004","volume":"69","author":"Nel M.S.","year":"2016","unstructured":"Nel M.S.; Petzer A.; Petzer J.P.; Legoabe L.J.; 2-Heteroarylidene-1-indanone derivatives as inhibitors of monoamine oxidase. Bioorg Chem 2016,69,20-28","journal-title":"Bioorg Chem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ejmech.2018.02.015","volume":"148","author":"Affini A.","year":"2018","unstructured":"Affini A.; Hagenow S.; Zivkovic A.; Marco-Contelles J.; Stark H.; Novel indanone derivatives as MAO B\/H3R dual-targeting ligands for treatment of Parkinson\u2019s disease. Eur J Med Chem 2018,148,487-497","journal-title":"Eur J Med Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00044-010-9368-4","volume":"20","author":"Bansal R.","year":"2011","unstructured":"Bansal R.; Narang G.; Zimmer C.; Hartmann R.W.; Synthesis of some imidazolyl-substituted 2-benzylidene indanone derivatives as potent aromatase inhibitors for breast cancer therapy. Med Chem Res 2011,20(6),661-669","journal-title":"Med Chem Res"},{"key":"ref=23","first-page":"84","volume":"137","author":"Morpurgo C.","year":"1962","unstructured":"Morpurgo C.; Effects of antiparkinson drugs on a phenothiazine-induced catatonic reaction. Arch Intel Pharmaco 1962,137,84-90","journal-title":"Arch Intel Pharmaco"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1021\/acschemneuro.7b00303","volume":"9","author":"Singh R.","year":"2018","unstructured":"Singh R.; Thota S.; Bansal R.; Studies on 16,17-pyrazoline substituted heterosteroids as anti-Alzheimer and anti-Parkinsonian agents using LPS induced neuroinflammation models of mice and rats. ACS Chem Neurosci 2018,9(2),272-283","journal-title":"ACS Chem Neurosci"},{"key":"ref=25","unstructured":"Crystal Structure of TNF-alpha with a small molecule inhibitor. Available from:  (Accessed on: 23\/2\/2020)"},{"key":"ref=26","unstructured":"Crystal structure of an Interleukin-1 receptor complex. Available from:  (Accessed on: 23\/2\/2020)"},{"key":"ref=27","unstructured":"Crystal structure of human monoamine oxidase B (MAO B) in complex\nwith pioglitazone. Available from:  (Accessed on 26\/6\/2021)"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1100\/2012\/756357","volume":"2012","author":"Rubio-Perez J.M.","year":"2012","unstructured":"Rubio-Perez J.M.; Morillas-Ruiz J.M.; A review: Inflammatory process in Alzheimer\u2019s disease, role of cytokines. ScientificWorldJournal 2012,2012,1-15","journal-title":"ScientificWorldJournal"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(09)70062-6","volume":"8","author":"Hirsch E.C.","year":"2009","unstructured":"Hirsch E.C.; Hunot S.; Neuroinflammation in Parkinson\u2019s disease: A target for neuroprotection? Lancet Neurol 2009,8(4),382-397","journal-title":"Lancet Neurol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1126\/science.1116304","volume":"310","author":"He M.M.","year":"2005","unstructured":"He M.M.; Smith A.S.; Oslob J.D.; Flanagan W.M.; Braisted A.C.; Whitty A.; Cancilla M.T.; Wang J.; Lugovskoy A.A.; Yoburn J.C.; Fung A.D.; Farrington G.; Eldredge J.K.; Day E.S.; Cruz L.A.; Cachero T.G.; Miller S.K.; Friedman J.E.; Choong I.C.; Cunningham B.C.; Small-molecule inhibition of TNF-\u03b1. Science 2005,310(5750),1022-1025","journal-title":"Science"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/ni.1925","volume":"11","author":"Wang D.","year":"2010","unstructured":"Wang D.; Zhang S.; Li L.; Liu X.; Mei K.; Wang X.; Structural insights into the assembly and activation of IL-1\u03b2 with its receptors. Nat Immunol 2010,11(10),905-911","journal-title":"Nat Immunol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"8104","DOI":"10.1021\/jm100971t","volume":"53","author":"Shook B.C.","year":"2010","unstructured":"Shook B.C.; Rassnick S.; Osborne M.C.; Davis S.; Westover L.; Boulet J.; Hall D.; Rupert K.C.; Heintzelman G.R.; Hansen K.; Chakravarty D.; Bullington J.L.; Russell R.; Branum S.; Wells K.M.; Damon S.; Youells S.; Li X.; Beauchamp D.A.; Palmer D.; Reyes M.; Demarest K.; Tang Y.; Rhodes K.; Jackson P.F.; In vivo characterization of a dual adenosine A2A\/A1 receptor antagonist in animal models of Parkinson\u2019s disease. J Med Chem 2010,53(22),8104-8115","journal-title":"J Med Chem"}],"container-title":["Current Computer-Aided Drug Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573409919666221129155110","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/211371\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573409919666221129155110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T05:44:46Z","timestamp":1698644686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/211371\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573409919666221129155110","relation":{},"ISSN":["1573-4099"],"issn-type":[{"value":"1573-4099","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-06-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}